HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reported today an update on recent study results and development activities for the Company’s NX-1207 drug for benign prostatic hyperplasia (BPH). The results of the recently completed 2 year double blind follow-up study demonstrated the durable effect of the drug, which is of fundamental interest and importance to urologists and their patients. The study was conducted at 24 U.S. sites and involved 103 unselected patients.
